You are here

Development of a Tritiated Agonist Radioligand for the D2 Receptor

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43OD020186-01A1
Agency Tracking Number: R43OD020186
Amount: $148,426.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: OD
Solicitation Number: PA13-234
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
121 Middlesex Turnpike, Ste 5
BURLINGTON, MA 01803-4990
United States
DUNS: 926458290
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 (617) 855-3388
Business Contact
Phone: (781) 272-6888
Research Institution

DESCRIPTION (provided by applicant): The goal of this project is to develop a novel agonist radioligand for evaluating the proportion of D2 receptors in the high state. The D2high receptor is thought to be the functional form of the D2 receptor to which endogenous dopamine binds. An agonist radioligand should be more sensitive to endogenous DA levels than antagonist radioligands since, unlike antagonists, agonist radioligands bind preferentially to the receptor in its high affinity state. Thus, agonist radioligands have the potential to elucidate more detailed information on receptor subtype activity as a function of disease as well as DA system activity as a whole. The majority of available radioligands are based on D2 antagonists and, as such, do not specifically target the D2high state. Among the commercially available agonist ligands, none possess high selectivity for D2 over D3. In contrast, fluoroaporphines, which are the focus of this project, are D2 receptor agonists that specifically and select

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government